Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients

NCT02421588 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

442

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: Lurbinectedin (PM01183)
DRUG: Pegylated liposomal doxorubicin (PLD)
DRUG: Topotecan

Sponsor

PharmaMar